Supreme Court declines to hear biologic drug patent fight
WASHINGTON (Reuters) - The U.S. Supreme Court on Monday declined to hear a case over whether companies that make copycat versions of biologic drugs must wait six months after winning federal approval before bringing them to the market.
No comments:
Post a Comment